Eva Medtec offering is now closed and is no longer accepting investments.
INVEST IN EVA MEDTEC TODAY!
Automated Lymphatic Therapy (ALT) Technology
$130,533.50 Raised
REASONS TO INVEST
The Neuroglide™ by Eva Medtec makes it possible for anyone to experience the benefits of automated lymphatic therapy with one simple, at-home system. The company’s proprietary technology has received FDA-clearance for pain relief and increased circulation, which has numerous physical health benefits.
By developing non-invasive solutions that can be accessed without the need for a prescription, Eva Medtec is targeting the $4B Pain Management Devices market, which is expected to reach more than $8.5B by 2030 (8.5% CAGR). With additional therapy attachments currently in development, Eva Medtec also plans to address the $18.6B Stress Management Market as well as the $30B+ Sleep Health Market as the company looks to expand the Neuroglide’s FDA labeling.*
At the helm of Eva Medtec’s operations is a team of passionate founders with decades of combined medical and marketing experience seeking to continually evolve the company’s product pipeline with new innovations for the med-tech market. All products developed by Eva Medtec are based on extensive in-field expertise and are made in the U.S. by a full, in-house manufacturer.
*Market information provided by Precedence Research, Globe Newswire, and McKinsey & Company (source, source, source)
the pitch
Eva Medtec is the creator and manufacturer of Neuroglide™, an over-the-counter, FDA-cleared medical device engineered to automate and emulate manual lymphatic drainage (MLD) therapy. Lymphatic fluid carries toxins and other debri from cells of the body. When this fluid builds up in the lymphatic vessels, the body can have a number of negative reactions, including swelling and discomfort. MLD therapy seeks to accelerate lymph flow and decongest the body’s soft tissues of excess lymph, a practice with many associated health benefits – including pain management, improved rest, relaxation, and recovery.
Holistic Methodology Meets Modern Innovation
The Neuroglide™ is a back and neck device that emulates the precise pressure profiles and principles of manual lymphatic drainage (MLD) therapy in order to make this highly-specialized modality more available and accessible to all.
The technology was developed with the expertise of a certified MLD therapist, Eva Medtec's Founder & CTO, Irene Waldridge. Irene previously founded a publicly traded, market-leading lymphedema company, Tactile Medical (NASDAQ: TCMD), which at one point held a $1.2B market cap.* Irene’s experience practicing the techniques of MLD led her to witness its many health benefits firsthand. Because lymphatic therapy supports the body’s immune and autonomic nervous systems, MLD treatment has the potential to improve patient outcomes in cases of acute pain, injury, chronic pain, and other chronic conditions.
*Eva Medtec's leadership experience is not a guarantee of future performance or success.
The Problem & Our Solution
Bringing Together Technique and Technology to Provide Therapeutic At-Home Care
In recent years, more medical and therapeutic professionals have begun to recognize the body’s lymphatic system as having an important impact on overall health and wellness. Increased lymph circulation is linked to improved immune function, as well as reduction of swelling, congestion, and inflammation. However, because MLD therapy is an advanced modality available only through a handful of certified professional practitioners, most people aren’t able to access lymphatic therapy as often as needed for it to be truly effective.
(source)
Understanding this, Eva Medtec sought to develop a fully-automated device that can be used from the comfort of home, capable of producing benefits similar to receiving hands-on treatment. Utilizing an array of air channels that inflate and deflate in sequence, the Neuroglide™ is able to emulate the proper pressure, tempo, and mechanics needed to access the lymphatic system, promoting healthy flow of lymph throughout the entire body. This technology has been cleared by the FDA for pain relief and increased circulation, and is easy to use, anywhere, at any time.
The Market & Our Traction
Backed by Science and Built to Serve Multiple Market Verticals
In order to introduce the Neuroglide™ to the commercial market, Eva Medtec has obtained Class II FDA clearance for pain relief and increased circulation, as well as utility patent status for our proprietary technology. With these proof-positive elements in place, the company has been able to generate our first $100K in sales.
In pilot clinical patient trials, users of Neuroglide™ reported reduced back and neck pain, more restorative and consistent sleep, improved athletic recovery, and reduced pain from fibromyalgia.
As Eva Medtec works to expand awareness and accessibility to MLD therapy, the company is equally as excited about the planned, future therapy devices currently in development. These devices are designed for use with specific body regions such as the knee, lower legs, lumbar, and head, and work with the Neuroglide’s Controller Unit at launch. In addition to further developing the company’s product line, Eva Medtec also plans to expand Neuroglide’s FDA labeling into other benefit cases such as improved sleep, stress reduction, and athletic recovery.
Why Invest
Trusted Technology on Trend to Provide Positive Impact
As lymphatic therapies and MLD continue to generate a buzz in the medical sector as well as amongst A-list celebrities, such as Jennifer Aniston, the Kardashians, and Ariana Grande, Eva Medtec anticipates a growing trend of consumers looking to experience its many health benefits for themselves. Even so, because MLD remains a niche modality available only to a limited market, the company expects automated devices such as the Neuroglide™ have great potential to be widely embraced by at-home consumers.
With support from funding, Eva Medtec is poised for expansion and looks forward to offering an affordable, accessible solution that improves people’s daily lives. Be a part of Eva Medtec's mission by investing today!
Neuroglide™ is a Class II, over-the-counter FDA cleared medical device intended for the temporary relief of minor muscle aches and pains and for the temporary increase in circulation to the treated areas.
ABOUT
HEADQUARTERS
6300 W. Old Shakopee Road, Ste 140
Bloomington, MN 55438
WEBSITE
View Site
Eva Medtec is a medical technology enterprise that launched commercially in 2021 with its flagship product, the Neuroglide™, and has raised $3.7M to date.
TEAM
John Foster Dinusson
President & CEO
Irene Anne Waldridge
Founder/CTO
David Edward Rupp
VP of Marketing
Toni May Hastings
VP of Administration
Mark Melin, MD
Medical Director
Dan Sipple, DO
Medical Advisor
Doug Goldstein, DPT
Medical Advisor
TERMS
Eva Medtec
Overview
PRICE PER SHARE
$1.49
DEADLINE
Mar 21, 2023
VALUATION
$11.03M
AMOUNT RAISED
$130,533.50
Breakdown
MIN INVESTMENT
$299.49
MAX INVESTMENT
$1,234,999.91
MIN NUMBER OF SHARES OFFERED
6,711
OFFERING TYPE
Equity
ASSET TYPE
COMMON
SHARES OFFERED
Common Stock
MAX NUMBER OF SHARES OFFERED
828,859
Maximum Number of Shares Offered subject to adjustment for bonus shares
Company | : | Eva Medtec, Inc. |
Corporate Address | : | 6300 W. Old Shakopee Road, Ste 140, Bloomington, MN 55438 |
Offering Minimum | : | $9,999.39 |
Offering Maximum | : | $1,234,999.91 |
Minimum Investment Amount(per investor) | : | $299.49 |
Terms
Offering Type | : | Equity |
Security Name | : | Common Stock |
Minimum Number of Shares Offered | : | 6,711 |
Maximum Number of Shares Offered | : | 828,859 |
Price per Share | : | $1.49 |
Pre-Money Valuation | : | $11,026,421.67 |
*Maximum Number of Shares Offered subject to adjustment for bonus shares. See Bonus info below.
Voting Rights of Securities Sold in this Offering
Voting Proxy. Each Subscriber shall appoint the Chief Executive Officer of the Company (the “CEO”), or his or her successor, as the Subscriber’s true and lawful proxy and attorney, with the power to act alone and with full power of substitution, to, consistent with this instrument and on behalf of the Subscriber, (i) vote all Securities, (ii) give and receive notices and communications, (iii) execute any instrument or document that the CEO determines is necessary or appropriate in the exercise of its authority under this instrument, and (iv) take all actions necessary or appropriate in the judgment of the CEO for the accomplishment of the foregoing. The proxy and power granted by the Subscriber pursuant to this Section are coupled with an interest. Such proxy and power will be irrevocable. The proxy and power, so long as the Subscriber is an individual, will survive the death, incompetency and disability of the Subscriber and, so long as the Subscriber is an entity, will survive the merger or reorganization of the Subscriber or any other entity holding the Securities. However, the Proxy will terminate upon the closing of a firm-commitment underwritten public offering pursuant to an effective registration statement under the Securities Act of 1933 covering the offer and sale of Common Stock or the effectiveness of a registration statement under the Securities Exchange Act of 1934 covering the Common Stock.
Investment Incentives and Bonuses*
Time-Based:
Friends & Family Bonus
Invest within the first 48 hours and receive 20% bonus shares.
Super Early Bird Bonus
Invest within the first week and receive 10% bonus shares.
Early Bird Bonus
Invest within the first two weeks and receive 5% bonus shares.
Amount-Based:
$700
Invest $700 and receive 2% bonus shares.
$1,500+ | Tier 1
Invest $1,500 and receive 4% bonus shares.
$5,000+ | Tier 2
Invest $5,000 and receive 7% bonus shares + a Neuroglide + 30-minute call with CEO or Founder (expert in Lymphedema & MLD)
$10,000+ | Tier 3
Invest $10,000 and receive 15% bonus shares + a Neuroglide + 30-minute call with CEO or Founder (expert in Lymphedema & MLD)
$25,000+ | Tier 4
Invest $25,000 and receive 20% bonus shares + a Neuroglide + 30-minute call with CEO or Founder (expert in Lymphedema & MLD)
*In order to receive perks from an investment, one must submit a single investment in the same offering that meets the minimum perk requirement. Bonus shares from perks will not be granted if an investor submits multiple investments that, when combined, meet the perk requirement. All perks occur when the offering is completed.
The 10% StartEngine Owners' Bonus
Eva Medtec, Inc will offer 10% additional bonus shares for all investments that are committed by investors that are eligible for the StartEngine Crowdfunding Inc. OWNer's bonus.
This means eligible StartEngine shareholders will receive a 10% bonus for any shares they purchase in this offering. For example, if you buy 100 shares of Class B Non-Voting Common Stock at $3.20/share, you will receive 10 additional shares of Non-Voting Common Stock, meaning you'll own 110 shares for $320. Fractional shares will not be distributed and share bonuses will be determined by rounding down to the nearest whole share.
This 10% Bonus is only valid during the investor's eligibility period. Investors eligible for this bonus will also have priority if they are on a waitlist to invest and the company surpasses its maximum funding goal. They will have the first opportunity to invest should room in the offering become available if prior investments are canceled or fail.
Investors will receive the highest single bonus they are eligible for among the bonuses based on the amount invested and time of offering elapsed (if any). Eligible investors will also receive the Owner’s Bonus in addition to the aforementioned bonus.
Irregular Use of Proceeds
The Company might incur Irregular Use of Proceeds that may include but are not limited to the following over $10,000: Vendor payments. Salary payments made to one’s self, a friend or relative. Inter company debt or back payments.
ALL UPDATES
03.20.23
Last Day To Invest!
03.17.23
Meet our Medical Director Dr. Mark Melin.
Our Medical Director, Dr. Mark Melin is a surgeon and Medical Director of the M Health Wound Healing Institute (South Campus) and an Adjunct Associate Professor in the University of Minnesota Surgical Department.
His interests and educational niches include management of lymphedema/lymphatic stasis in the wounded patient, the endothelial glycocalyx, adjunctive micronutrient and bionutrient application to wound care, diosmin Micronized Purified Flavonoid Fraction (MPFF), polygenic abnormality impact upon wound resolution, wound pH and biofilm management, and emerging technologies in wound products and wound technologies.
Neuroglide utilizes a precise, rhythmic, sequential, calibrated consistent pressure profile to help speed up healing by removing cellular waste associated with pain and inflammatory circulatory conditions. The system is patented and incorporates proprietary therapy programs with customized materials to produce a unique power to relax, relieve pain and recover. It’s affordable, convenient, and improves quality of life.
To view the lymphatic fluid moving in the vessels, Dr. Melin and his lymphatic expert team is looking forward to conducting our pilot NIRFLI study at UTHealth (University of Texas). This study will show the first unimpeded visualization of the torso. The imaging will show lymphatic drainage vessel propulsion and velocity while using the Neuroglide. We will see the results of the study several weeks later.
We want to thank all of you who have invested in Eva Medtec and support our goal to bring this breakthrough product that has the unique power to relax, relieve pain and recover. We look forward to updating you with more exciting news!
– Eva Medtec
03.13.23
Announcement CSO
We are excited to announce we have added a Chief Scientific Officer to our team!
We are pleased to announce Joy L Frestedt, PhD, CPI, RAC, FRAPS has joined our team. She is our new Chief Scientific Officer. Dr. Frestedt will head up our Clinical Research ∙ Regulatory Affairs ∙ Quality Systems ∙ Biomedical Engineering efforts.
Dr. Frestedt has a strong reputation for building cohesive, results-oriented teams and for developing and implementing strategic business plans. Over 35 years in regulatory, scientific, clinical and quality affairs as well as project and program management, staff development, grants administration and operations. Outstanding abilities include planning, prioritizing and facilitating business growth. Expertise in initiating, developing and reviewing clinical, regulatory and quality operations. Extensive written and oral communications with teaching and training experience for many different teams including platform presentations, writing and editing manuscripts, study reports, clinical and regulatory documents, market research, literature reviews, safety summaries, and brochures. Author of FDA Warning Letters about Food Products: How to Avoid or Respond to Citations (Elsevier, in press, August 2017) and Warning Letters: 2016 Reference Guide (Barnett International, 2016).
HONORS 2016 Frestedt Inc. Awarded Best Biotechnology Clinical Research - Minnesota (GHP Magazine) 2015 Appointed to NSF Publicly Available Statement (PAS) Generally Regarded as Safe (GRAS) panel 2011 “100 Most Inspiring People in the Life Science Industry” (PhamraVOICE) 2011 Top 25 “Industry Leaders” a “Women in Business Award” (MSP Business Journal).
– Eva Medtec
03.10.23
Eva Medtec most recent update
3.10.23
We received notice that our second patent is expected to be issued in March 2023.
It’s another exciting milestone, we are in receipt of an issue notification from the Patent Office in connection to our continuation-in-part (CIP) application with claims directed to a diverter (Valve Module) for delivering air to a plurality of exit ports in a predetermined manner.
Our StartEngine Funding Campaign is closing next week, so we want to thank all of those who believed in us and invested in Eva Medtec. We will keep you updated. If you know of anyone who may be interested in investing, there is still some time left, so please pass this information onto them.
Please check out our website Neuroglide.com for new information.
– Eva Medtec
03.03.23
Join us today and invest in Eva Medtec! Help us make a difference in the quality of lives of those who suffer daily from chronic pain.
Join us today and invest in Eva Medtec! Help us make a difference in the quality of lives of those who suffer daily from chronic pain.
Simulated Manual Lymph Drainage Therapy for In-Home Treatment
of Acute/Chronic Pain
Written by M. Mark Melin MD FACS RPVI FACCWS and Irene Waldridge, CMT, CLT
See our White Paper at neuroglide.com
We are so excited to announce that Eva Medtec has reached over $100K investment from 37 investors! We are specifically grateful that our investor community believes in our mission to removing lymphatic inflammation as a gateway to relieving back/neck pain. Eva Medtec has already proven that Manual Lymphatic Drainage (MLD) Therapists are seeing amazing results across the country and they are gaining revenue through offering Neuroglide add-on services. Hospitals are using the Neuroglide for their healthcare workers, and physicians are referring their patients who have had workers compensation injuries.
Eva Medtec
02.15.23
The impact we are having on pain mitigation is remarkable. Invest in change!
There’s a rationale for our automated Neuroglide’s MLD-like therapy. 50M people in the US suffer from chronic pain, so we are excited Neuroglide is making a difference!
Further we are excited to investigate the biochemical and NIRFLI lymphatic imaging research to determine the potential physiological connections for Neuroglide’s cranial sacral stimulation and MLD’s synergistic actions for pain management.
Thank you for your support and belief in our ability to change the pain management device world!
We are grateful to see new and returning investors! Are you ready to join them? The minimum to invest is just $299.49.
– Eva Medtec
01.26.23
We are excited to disrupt the Manual Lymphatic Drainage (MLD) market like never before!
Amazing News! Manual Lymphatic (MLD) therapists, physicians and patients are so amazed to see neck/back pain relief and improved circulation, many of them are investing in Eva Medtec.
We are so excited to share with you the Neuroglide’s automated MLD technology has been proving its value in treating patients in hospitals, clinics, and at-home.
We are grateful to see new and returning investors! Are you ready to join them? The minimum to invest is just $299.49.
– Eva Medtec
01.19.23
Meet Our President and Chief Executive Officer!
My Passion Is Delivering Extraordinary Results!
For over 25+ years, I have been an entrepreneur and Executive Leader in Medical Devices delivering extraordinary results.
My background with fundraising, strategic planning, business development, and commercialization drives results in growth, revenue, operational performance, and profitability through innovative commercial strategies and highly successful product launches.
My next-generation leadership through coaching and accountability, strong ethics, intellectual curiosity, passion, and commitment help improve lives. My collaborative and transformational leadership will add strength to our vision and mission at Eva Medtec.
As an adjunct faculty member for the University of Minnesota, I taught graduate classes in the School of Engineering and the Medical Device Innovation Program. My experience developing drug-free, non-invasive, and mobile medical technology, helps patients manage pain, regain physical function, and contribute to an active lifestyle.
As the founder, President and CEO of OrthoCor Medical, we developed of drug-free, non-invasive, and mobile medical technology, using pulsed electromagnetic field (PEMF) technology to help patients manage pain, regain physical function, and contribute to an active lifestyle. I raised $6.5M in equity financing and built the company from inception to exceptional YoY revenue growth. I helped secure four FDA clearances, and collaborated with Q&A, R&D, and manufacturing to launch nine next-generation products.
My Personal Interests
I studied a year abroad in Nepal, Tibet, and India, co-produced an internationally televised Tibetan Freedom Concert that raised over $1M, and served in the U.S. House of Representatives Congressional Page School my junior year of high school.
Best Regards,
John Dinusson
President and CEO
01.13.23
Meet the Founder of Eva Medtec!
Ms. Irene Waldridge pushes through all challenges and obstacles
to help improve patients’ quality of life.
Our founder and Chief Technology Officer, Irene Waldridge, is a certified massage and lymphatic drainage (MLD) therapist. She has 27 years of experience inventing, developing, and marketing automated Lymphatic Therapy (ALT) medical devices. She is the founder of two medical device companies, Eva Medtec and Tactile Medical.
After receiving her MLD training on the anatomy and physiology of the lymphatic system, Ms. Waldridge embarked on a lifelong pursuit of engineering devices that automate MLD therapy. Her deep desire is to improve the quality of peoples’ lives by treating lymphedema, venous insufficiency, relieving pain, improving lymphatic circulation and improving sleep recovery.
Tactile Medical
Ms. Waldridge founded Tactile Medical, a public company with a market value of $1.3 billion prior to COVID. At Tactile, Irene’s dedication to advancing the standard of care for treating lymphedema and vascular diseases at-home became a reality. She invented the innovative Flexitouch® system, which has helped over 100,000 patients.
Eva Medtec, Inc.
Irene is the inventor of the Neuroglide™ system, an over-the-counter, FDA-cleared medical device that automates MLD therapy for the treatment of neck/back pain and increased circulation. Her commitment to relieving pain, and increasing lymphatic circulation will lead to other treatments such as post-op swelling (edema), injuries, lymphedema, and improving sleep.
If you would like to speak to Irene directly, you may call 612-251-3949 or email her at iwaldridge@evemedtec.com
Best Regards,
John Dinusson
President and CEO
01.11.23
Learn more about Eva Medtec’s pilot sleep study.
Pain Management Device Market
The 2021 US Sleep Device Market was estimated at $15 billion and is expected to increase to $67.7 billion in 2030 with a CAGR of 18.1%. Painful neck and back problems are pervasive and associated with chronic pain, disability and high healthcare utilization.
Chronic Pain Affects Sleep Quality – Doug Goldstein, Doctor of Physical
Therapy (DPT)
Eva Medtec Medical Advisor, Doug Goldstein, conducted a pilot sleep study to determine what effect the Neuroglide™ system has on sleep recovery. Participants used a wearable device validated for measuring heart rate variability, resting heart rate, strain, and REM/deep sleep. The study was designed to measure sleep biometrics for a total of 14 days. A 7-day baseline pretest without using Neuroglide, followed by a 7-day test period using the Neuroglide for half hour prior to their regular sleep period. The results of this study revealed an improvement in recovery (+14.6% for test period as a group), with an increase in HRV as well as Deep and REM sleep overall. This study indicates the Neuroglide system increases a person’s parasympathetic (rest and digest) response and may help promote relaxation that can lead to improved sleep and/or recovery.
Best Regards,
John Dinusson
President and CEO
Stack Owner's Bonus & Rewards!
Members get an extra 10% shares in addition to rewards below!
REWARDS
$299
Earn 10% Bonus Shares
Earn 10% bonus shares in this investment and all eligible investments for an entire year. If you are not already an Owners bonus holder, you can join now, for $275, billed annually.
$700
Tier 1
Invest $700 and receive 2% bonus shares.
$1,500
Tier 2
Invest $1,500 and receive 4% bonus shares.
$5,000
Tier 3
Invest $5,000 and receive 7% bonus shares + a Neuroglide + 30-minute call with CEO or Founder (expert in Lymphedema & MLD)
$10,000
Tier 4
Invest $10,000 and receive 15% bonus shares + a Neuroglide + 30-minute call with CEO or Founder (expert in Lymphedema & MLD)
$25,000
Tier 5
Invest $25,000 and receive 20% bonus shares + a Neuroglide + 30-minute call with CEO or Founder (expert in Lymphedema & MLD)
JOIN THE DISCUSSION
0/2500
HOW INVESTING WORKS
Cancel anytime before 48 hours before a rolling close or the offering end date.
WHY STARTENGINE?
REWARDS
We want you to succeed and get the most out of your money by offering rewards and memberships!
SECURE
Your info is your info. We take pride in keeping it that way!
DIVERSE INVESTMENTS
Invest in over 200 start-ups and collectibles!
With Regulation A+, a non-accredited investor can only invest a maximum of 10% of their annual income or 10% of their net worth per year, whichever is greater. There are no restrictions for accredited investors.
With Regulation Crowdfunding, non-accredited investors with an annual income or net worth less than $124,000, are limited to invest a maximum of 5% of the greater of those two amounts. For those with an annual income and net worth greater than $124,000, he/she is limited to investing 10% of the greater of the two amounts.
At the close of an offering, all investors whose funds have “cleared” by this time will be included in the disbursement. At this time, each investor will receive an email from StartEngine with their Countersigned Subscription Agreement, which will serve as their proof of purchase moving forward.
Please keep in mind that a company can conduct a series of “closes” or withdrawals of funds throughout the duration of the campaign. If you are included in that withdrawal period, you will be emailed your countersigned subscription agreement and proof of purchase immediately following that withdrawal.
StartEngine assists companies in raising capital, and once the offering is closed, we are no longer involved with whether the company chooses to list shares on a secondary market, or what occurs thereafter. Therefore, StartEngine has no control or insight into your investment after the close of the live offering. In addition, we are not permitted to provide financial advice. You may want to contact a financial professional to discuss possible investment outcomes.
For Regulation Crowdfunding, investors are able to cancel their investment at any point throughout the campaign up until 48 hours before the closing of the offering. Note: If the company does a rolling close, they will post an update to their current investors, giving them the opportunity to cancel during this timeframe. If you do not cancel within this 5-day timeframe, your funds will be invested in the company, and you will no longer be able to cancel the investment. If your funds show as ‘Invested’ on your account dashboard, your investment can no longer be canceled.
For Regulation A+, StartEngine allows for a four-hour cancelation period. Once the four-hour window has passed, it is up to each company to set their own cancelation policy. You may find the company’s cancelation policy in the company’s offering circular.
Once your investment is canceled, there is a 10-day clearing period (from the date your investment was submitted). After your funds have cleared the bank, you will receive your refund within 10 business days.
Refunds that are made through ACH payments can take up to 10 business days to clear. Unfortunately, we are at the mercy of the bank, but we will do everything we can to get you your refund as soon as possible. However, every investment needs to go through the clearing process in order to get sent back to the account associated with the investment.
Both Title III (Regulation Crowdfunding) and Title IV (Reg A+) help entrepreneurs crowdfund capital investments from unaccredited and accredited investors. The differences between these regulations are related to the investor limitations, the differing amounts of money companies are permitted to raise, and differing disclosure and filing requirements. To learn more about Regulation Crowdfunding, click here, and for Regulation A+, click here.
